ABSTRACT
INTRODUCTION
It has been claimed that several technical aspects of embryo transfer (ET) affect the probability of pregnancy in human in-vitro fertilization (IVF). The type of catheter 1 , operator's skill 2 , site of embryo discharge 3 -6 , contamination with mucus or blood 7 , uterine contractions and level of difficulty in passing through the cervix 8, 9 have all been evaluated as factors potentially affecting IVF outcome. For a number of years, ET was performed by inserting the catheter into the cervix and blindly discharging the embryos approximately in the middle of the uterine cavity (termed 'clinical touch' ET). However, the use of ultrasound imaging to guide ET was introduced progressively in order to control better the site of embryo placement; transabdominal ultrasound guidance allows visualization of the catheter tip in real time, and the echogenic spot seen immediately after embryo discharge allows a precise estimate of embryo position after transfer. Several systematic reviews of randomized trials have reported that transabdominal ultrasound-guided ET (TA-UGET) is more effective than is clinical touch 10 -13 , with the most recent reporting a significant benefit of ultrasound guidance in terms of clinical pregnancy and live birth 14 .
Alternatively, the use of transvaginal ultrasound to guide ET (TV-UGET) has been proposed 15, 16 , with claims that it could be preferable in some patients (e.g. those overweight or with uterine retroversion), more tolerable (with no requirement for a full bladder) and more convenient (needing only a single operator) in comparison to TA-UGET. TV-UGET was tested in retrospective trials 17, 18 and was compared with TA-UGET in two randomized controlled trials (RCTs) 19, 20 that showed comparable IVF outcome, but that were underpowered to reach convincing conclusions. Moreover, the proposed TV-UGET technique seems to be relatively difficult for the physician and uncomfortable for the patient because it requires the speculum, vaginal probe and transfer catheter to be inserted into the vagina, and to date it has not been widely implemented.
The aim of the present RCT was to test an ET technique based on uterine length measurement before transfer (ULMbET), in which transvaginal ultrasound was used to calculate the optimal site of embryo discharge prior to rather than during ET, and to compare its performance with that of TA-UGET in a large number of patients. ULMbET is less technically challenging for the operator and more comfortable for the patient than is TV-UGET, but retains the advantages of TV-UGET over TA-UGET.
SUBJECTS AND METHODS
The trial was designed as a non-inferiority trial in which TA-UGET was considered the control method and ULMbET the experimental method, and was approved by the local ethical committee and registered retrospectively (ClinicalTrials.gov no. NCT02526472; August 2015). CONSORT guidelines were followed in the reporting of the trial 21, 22 .
Patients
Women undergoing IVF at our unit who matched the following a-priori eligibility criteria were invited to enroll in the study: (i) age < 43 years, (ii) absence of a uterine cause of infertility, and (iii) a-priori agreement to receive the transfer of one to three cleavage-stage (48-72 h) fresh embryos. Patients with the following features were excluded: (i) age ≥ 43 years, (ii) uterine anatomical abnormalities proven to reduce implantation and pregnancy rates (e.g. malformations, myomas, endometrial polyps), and (iii) the wish to continue embryo culture to blastocyst stage and receive ET on day 5-6. Enrolled patients signed a detailed informed consent form. Patients for whom it was necessary to change the catheter during ET for cervical stenosis were also excluded from the final analysis because the use of a stiffer catheter may affect IVF outcome.
In-vitro fertilization protocol and management
Controlled ovarian stimulation (COS) was performed with administration of a starting dose of 100-300 IU/day recombinant follicle-stimulating hormone (Gonal F ® , Merck Serono, Darmstadt, Germany or Puregon ® , MSD, Hoddesdon, UK) or human menopausal gonadotropin (Meropur ® , Ferring Pharmaceuticals, Saint Prex, Switzerland). The choice of the starting dose was based on age, body mass index, antral follicle count, basal (day 3) FSH, and anti-Müllerian hormone. On day 6-7 of ovarian stimulation, the gonadotropin dose was adapted according to the ovarian response. Gonadotropins were administered using a 'long' protocol with gonadotropin-releasing hormone (GnRH) agonists or a 'short' protocol with GnRH antagonists. The classical 'long' protocol was performed with administration of the GnRH agonist buserelin (Suprefact ® , Hoechst, Höchst, Germany; 900 μg/day intranasally) from day 21 of the incoming cycle. After approximately 2 weeks, pituitary suppression was verified (appearance of menstrual bleeding, serum estradiol < 50 pg/mL, endometrial thickness < 3 mm) before initiation of COS. In the 'short' protocol, the GnRH antagonist cetrorelix (Cetrotide ® , Merck Serono) or ganirelix (Orgalutran ® , MSD) was started at a subcutaneous dose of 0.25 mg/day when at least one follicle ≥ 14 mm diameter was observed, according to a flexible schedule.
The COS was monitored by serial transvaginal ultrasound plus serum estradiol measurements performed every second day from stimulation day 6-7. From stimulation day 6-7 onward, COS continued until at least one dominant follicle reached 18 mm diameter, with appropriate estradiol levels. At this point, ovulation was triggered by subcutaneous injection of 10 000 IU of human chorionic gonadotropin (hCG) (Gonasi HP ® , IBSA, Lugano, Switzerland), and transvaginal ultrasound-guided oocyte aspiration (oocyte pick-up) was performed under local anesthesia (paracervical block) approximately 36-37 h later. Classical IVF or intracytoplasmic sperm injection was performed according to clinical indication. After 2-3 days of in-vitro culture, embryos were scored according to Holte et al. 23 and one to three embryos were transferred to the uterus. If several embryos with good scores were obtained, surplus embryos were frozen and kept in liquid nitrogen for further use. The luteal phase was supported by administration of 180 mg/day natural progesterone (Crinone 8 ® , Merck Serono) for 15 days. Pregnancy was assessed by serum hCG assay 15 days after ET and then confirmed if at least one gestational sac was visualized at transvaginal ultrasound after a further 2 weeks; another ultrasound check was scheduled at 10 weeks in order to ensure that pregnancy was ongoing.
Embryo transfer technique
All cases included in the final analysis received ET on day 2-3 of embryo culture with one to three fresh embryos derived from autologous IVF. The Aloka SSD 1700 ultrasound machine equipped with transabdominal probe Convex 4C or with 6.5-MHz transvaginal probe C8ECS was used in all cases. According to our usual clinical practice, no mock or trial ET was performed.
The patient was placed in the lithotomy position, and the cervix was exposed using a speculum. The cervix was then gently cleaned using saline solution and the cervical mucus leaking out from the cervical os was removed using wet gauze.
In order to avoid any bias linked to the operator's experience and skill, all ETs were performed by one of three experienced doctors who used the same soft catheter (Sydney ® , Cook, Melbourne, Australia) loaded by experienced biologists with a constant amount (20 μL) of culture medium. The Sydney catheter was used for all randomized patients, but if cervical stenosis was encountered and ET was difficult then the catheter was changed, shifting to a stiffer one (TDT ® , Laboratoire CCD, Paris, France) and these cases were excluded from the final analysis. However, an intention-to-treat analysis retaining these patients was also performed. Neither a tenaculum nor suture points placed on the cervix to pull it were used in any case.
A gentle and slow insertion of the stiffer outer sheath of the Sydney catheter was performed and, after insertion of the softer inner cannula carrying the embryos, they were gently discharged and the catheter was retracted very slowly. The catheter was immediately and carefully checked under a microscope and if embryos had been retained they were reharvested in order to immediately repeat the transfer procedure. These cases were included in the final analysis. The presence of blood inside the cannula was recorded. The overall time needed to perform ET (defined as the time elapsed from the loaded catheter being handed to the physician to the time of it being returned to the biologist after embryo discharge) was measured and recorded. The patient's discomfort during the ET procedure was assessed a few minutes after ET by administration of a visual analog scale (VAS) questionnaire (0-10 points, from no to extreme discomfort). Instructions on how to answer the questionnaire were given orally by a physician before ET; a few minutes after ET the patient gave a written reply to the questionnaire and the questionnaire was collected before the patient left the IVF Unit.
When TA-UGET was used ( Figure 1 ), a second physician assisted the ET, performing transabdominal ultrasound imaging, and the embryos were discharged when the tip of the catheter was visualized at approximately 1.5 cm from the fundal endometrial surface, which was observed to be the best placement site in previous research by our group 6 . When ULMbET was scheduled (Figure 1) , the physician performed a transvaginal ultrasound scan just before ET, visualizing the uterus in a sagittal plane, and measured the length of the cervix and calculated the distance between the internal uterine os and the fundal endometrial surface. The probe was then removed from the vagina, a speculum was inserted and ET was performed by clinical touch, inserting the inner cannula of the Sydney catheter (which has length markers on it) in order to discharge the embryos at a point obtained by subtraction of 1.5 cm from the total length of the cavity.
Immediately after either TA-UGET or ULMbET, the position of the echogenic spot(s) inside the uterus, The probe is then removed from the vagina and ET is performed by clinical touch, inserting the inner cannula of the Sydney catheter (which has length markers on it) in order to reach the desired site of embryo discharge (C), calculated by subtraction of 15 mm (C-D) from the total length of the uterine cavity.
corresponding to air bubbles loaded with the embryos, was checked by transvaginal ultrasound and after approximately 30 s its distance (or the distance of a virtual point in the middle of two spots in such cases) from the fundal endometrial surface was measured, providing the final position of embryo placement.
Statistical analysis
Primary outcomes of the study were clinical pregnancy rate and ongoing pregnancy rate at 10 weeks per ET (clinical pregnancy rate per ET and ongoing pregnancy rate per ET), as well as implantation rate. Secondary outcomes were the following: twinning rate, ectopic pregnancy rate, duration of ET procedure, distance of the echogenic spot(s) from the fundal endometrial surface, percentage of cases without visible echogenic spot(s), percentage of cases with repeat ET, percentage of ET with blood-stained catheter (blood inside the inner cannula after ET), intensity of patient's discomfort (VAS scale points) during ET, and proportion of patients feeling moderate-to-severe discomfort (defined as VAS > 3 points).
A power analysis was performed using the PS ® software to estimate the required sample size. We considered TA-UGET to be the standard (control) technique and ULMbET as an experimental technique; a non-inferiority trial was designed and the power analysis was performed accordingly. We chose a predetermined difference between the transfer methods that would be significant enough to affect our clinical practice; this was a 5% difference in the clinical pregnancy rate between the two groups (considering an average 40% clinical pregnancy rate observed previously with the standard technique). In order to achieve an 80% power to show such a difference with α = 0.05, a sample size of 1636 cases (818 for each arm) was found to be required. This sample size was also sufficient to show an 8% increase in implantation rate (in the range of 20% to 28%) and an 8% increase in ongoing pregnancy rate per ET (in the range of 27% to 35%) with α = 0.05.
Randomization was performed on the day of ET with a 1 : 1 ratio using a computer-generated algorithm with no restrictions or blocks. In order to implement the random allocation sequence, a third person (laboratory secretary) looked at the randomized list (to which the doctors remained blinded) and communicated the randomized assignment by telephone (allocation concealment). Blinding was not applied to the assignment in each case as neither the operator nor the patient could be unaware of which transfer technique was being carried out. IVF outcomes were assessed using laboratory (hCG test) and ultrasound (transvaginal ultrasound at 7 weeks) procedures that were performed by other operators who did not know which ET technique had been used previously.
The distribution of the measured variables was analyzed using the Kolmogorov-Smirnov test and, as most data were not normally distributed, the two-sample Wilcoxon rank-sum (Mann-Whitney) test was used for comparison of continuous variables between groups, with results presented as median and interquartile range. The chi-square test was used to compare percentages. P-values < 0.05 were considered to be statistically significant.
RESULTS
The flow diagram of the study according to the CONSORT guidelines 21, 22 is shown in Figure 2 . A total of 1884 women undergoing IVF between September 2011 and September 2014 at our IVF Unit and matching the a-priori eligibility criteria were invited to enroll in the study, but 108 of them declined or were immediately excluded (58 because they declined to be part of an experimental trial, 50 due to the wish to continue embryo culture to the blastocyst stage). An additional 38 patients were excluded because the IVF cycle was stopped before reaching ET (no adequate response to COS, no fertilized oocytes, no available embryos). Overall, 1738 patients were enrolled into the study and randomized on the day of ET with a 1 : 1 ratio into two groups: 866 patients were scheduled to undergo TA-UGET, whereas 872 patients were scheduled to receive ULMbET. However, during ET, 90 patients (44 in the ULMbET group and 46 in the TA-UGET group) required a change of catheter because of cervical stenosis and consequently were excluded from the final analysis. The data from 1648 patients (828 in the ULMbET group vs 820 in the TA-UGET group) were therefore analyzed (Figure 2) .
The baseline clinical, hormonal and ultrasound characteristics of the patients included in the final analysis are presented in Table 1 ; the two groups of patients did not differ significantly in any of the variables considered. Similarly, the outcome of COS and the fertilization rate were comparable in the two groups, leading to a comparable final embryo availability and morphological score ( Table 2 ). The mean number of embryos transferred to the uterus was similar in the two groups and the endometrial thickness recorded during ET was comparable ( Table 2) .
Regarding the primary outcomes, there was no significant difference between the ULMbET and TA-UGET groups in clinical pregnancy rate per ET (38.2% vs 38.9%; odds ratio (OR), 1.141 (95% CI, 0.709-1.837)), implantation rate (24.8% vs 25.2%; OR, 1.089 (95% CI, 0.603-1.967)) or ongoing pregnancy rate per ET (33.1% vs 34.8%; OR, 0.986 (95% CI, 0.721-1.347)) ( Table 2) . For the secondary outcomes, the miscarriage and twinning rates were comparable in the two groups and there were three tubal pregnancies in the TA-UGET group (0.36%) vs none in the ULMbET group ( Table 2 ). The duration of transfer procedure was slightly shorter in the ULMbET group and there was no significant difference between the groups in the distance between the echogenic spot(s) and the endometrial fundus, or in the proportion of cases without an echogenic spot ( Table 2 ). The proportions of cases with repeat ET and of ET with blood in the catheter were similar (Table 2) .
Using the VAS to evaluate discomfort during ET, a significantly higher level of discomfort was observed using TA-UGET (2.6 vs 1.5 VAS points; P = 0.045) ( Table 2) . The proportion of patients with moderate-to-severe discomfort (VAS > 3, a threshold that was chosen because it has previously been found to be the mean discomfort level reported by patients during menstruation) was also significantly higher in the TA-UGET group (19.8% vs 1.2%; P = 0.003). The observed difference was probably due to the requirement for the patient to maintain a full bladder while TA-UGET was performed.
The intention-to-treat analysis of the primary outcomes, which included the 90 patients who required a change of catheter during ET for cervical stenosis, confirmed the lack of significant differences between the TA-UGET and ULMbET groups (Table 3) . Cases requiring a change of catheter occurred in a similar proportion in the two study groups (5.3% vs 5.0% in the TA-UGET and ULMbET groups, respectively). Data are presented as median (interquartile range), n/N (%) or %. AMH, anti-Müllerian hormone; BMI, body mass index; FSH, folliclestimulating hormone; IUI, intrauterine insemination; IVF, in-vitro fertilization.
DISCUSSION
Several systematic reviews of RCTs 10 -14 have compared the results of the 'blind' clinical touch transfer technique with those of the transabdominal ultrasound-guided transfer (i.e. TA-UGET), overall reporting some benefit of TA-UGET. The TA-UGET procedure straightens the angle between the cervix and uterus and this may facilitate ET, contributing to the observed improvement in results in comparison to clinical touch. There are, however, also some disadvantages to this technique: (i) ultrasound equipment and a second operator (physician or nurse) with adequate training in transabdominal ultrasound are needed, increasing the costs; (ii) the use of ultrasound to determine the location of the catheter tip is suboptimal in overweight-obese patients or in cases of uterine retroversion; movement of the catheter inside the uterus may be needed to better identify its position, but this may potentially damage the endometrium; (iii) more time is needed to perform TA-UGET in comparison to clinical touch; and (iv) the patient must maintain a full bladder while the procedure is performed; this may cause discomfort and cramping, which could be severe if a delay occurs, and the patient's discomfort, in turn, may stimulate uterine contractions.
As an alternative to the standard TA-UGET procedure, the use of TV-UGET has also been proposed 15, 16 , which provides several potential advantages: it does not require a full bladder, allows optimal detection of the uterocervical angle even in cases of uterine retroversion or overweight patients, and provides better visualization of the catheter tip than does transabdominal ultrasound. Two retrospective studies reported significantly better IVF outcome using TV-UGET in comparison to clinical touch 17, 18 , and two more recent RCTs comparing TV-UGET vs TA-UGET reported comparable clinical Data are presented as median (interquartile range) or n/N (%). *Embryos were scored according to Holte et al. 23 . †Three ectopic pregnancies were included as miscarriages. ‡If two spots were visible, the distance was calculated from a virtual point between them and the fundal endometrial surface. §Visual analog scale (VAS) = 3 was the mean discomfort level reported by patients to occur during the first day of menstruation. 23 . †Three ectopic pregnancies were included as miscarriages. pregnancy and implantation rates 19, 20 . In TV-UGET, the speculum, vaginal ultrasound probe and the outer, rigid part of the transfer catheter are held simultaneously in the vagina for several seconds. The inner, softer part of the catheter, loaded with the embryos, is then inserted following removal of the speculum, but with the probe retained in the vagina during embryo discharge 19, 20 . This technique is technically challenging, requiring manual dexterity if performed by a single operator, and it is likely to be uncomfortable for the woman.
In the present study we tested a more simple ET technique (in comparison to the others using ultrasound guidance) based on prior uterine length measurement (ULMbET), in which transvaginal ultrasound was used just before ET in order to measure the uterine length, which was then used to calculate the optimal site for embryo discharge. Clinical touch was then performed, with the embryo-loading cannula guided to the previously calculated discharge site. The use of uterine length measurement followed by clinical touch has been reported to provide the same IVF outcomes as TA-UGET in a retrospective study on 730 women in which historical controls were used 24 . Equivalence of the two methods was also observed in a small prospective randomized study including 26 patients 25 , whereas another larger randomized trial (200 patients) showed slightly higher implantation and pregnancy rates in the group receiving clinical touch with previous uterine length measurement 26 . In the present study, we prospectively compared TA-UGET and ULMbET in a large number of patients undergoing IVF with fresh ET and using only one type of transfer catheter. The trial was designed as a non-inferiority trial and was adequately powered (high number of events) to detect a clinically relevant difference in IVF outcome between TA-UGET and ULMbET groups.
We observed that the ULMbET technique allowed IVF outcomes to be obtained that were comparable to TA-UGET in terms of implantation rate and clinical and ongoing pregnancy rates. However, the time required to carry out ULMbET was slightly shorter, and the procedure was significantly better tolerated by patients, who could avoid the discomfort due to prolonged bladder distension.
We also observed that the ULMbET procedure is easy to teach to young doctors who have some experience in transvaginal ultrasound, and that it is easy for the procedure to be performed by a single operator and to be standardized between physicians with different levels of manual skill. Moreover, the ultrasound measurements for ULMbET may also be scheduled during cycle monitoring or during oocyte pick-up (saving time on the day of ET), and furthermore it may also be performed using transabdominal ultrasound, with the advantage of avoiding uterine manipulation with the probe just before ET.
The present study does have a number of limitations. Firstly, the operator and patient could not be blinded to the different transfer techniques. Secondly, the randomization was not stratified according to the operator who performed the transfer. Thirdly, we did not consider the live birth rate. However, we did not observe any significant differences between the two groups regarding possible confounding factors such as embryo morphological score, endometrial thickness, indication for IVF, operator's skill, etc. Although registered retrospectively, the protocol did not undergo any change throughout the duration of the study.
In conclusion, we observed that ULMbET leads to IVF results comparable to those obtained with TA-UGET, with the procedure being better tolerated by patients. It could therefore be proposed in routine clinical practice for those wishing to apply ultrasound assistance to ET on a large scale.
